About this Journal Submit a Manuscript Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2012 (2012), Article ID 957082, 8 pages
http://dx.doi.org/10.1155/2012/957082
Research Article

First Nationwide Attitude Survey of Japanese Physicians on the Use of Traditional Japanese Medicine (Kampo) in Cancer Treatment

1Aoyama Pharmacy, 2-10-9 Minami-Aoyama, Minato-ku, Tokyo 107-0062, Japan
2Center for Kampo Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
3Pharmaceutical Education Research Center, School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan

Received 29 April 2012; Accepted 5 September 2012

Academic Editor: Thomas Ostermann

Copyright © 2012 A. Ito et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. M. Robinson and X. Zhang, “The world medicines situation 2011,” Traditional medications: global situation, issues and challenges. World Health Organization Geneva, http://www.who.int/medicines/areas/policy/world_medicines_situation/WMS_ch18_wTraditionalMed.pdf, 2011.
  2. M. A. Richardson, T. Sanders, J. L. Palmer, A. Greisinger, and S. E. Singletary, “Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology,” Journal of Clinical Oncology, vol. 18, no. 13, pp. 2505–2514, 2000. View at Scopus
  3. E. C. Moschic, C. Mercado, T. Yoshino, K. Matsuura, and K. Watanabe, “Usage and attitudes of physicians in Japan concerning traditional Japanese medicine (Kampo medicine)—a descriptive evaluation of a representative questionnaire-based survey,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 139818, 13 pages, 2012. View at Publisher · View at Google Scholar
  4. Ministry of Health, Labour and Welfare, “Cancer control,” http://www.mhlw.go.jp/english/wp/wp-hw2/part2/p3_0026.pdf, 2012.
  5. United Nations World Population Prospects, http://www.un.org/esa/population/publications/wpp2008/wpp2008_highlights.pdf, 2008.
  6. The World Health Report 2004 Annex Table 4 Healthy life expectancy (HALE) in all Member Stateshttp://www.who.int/whr/2004/annex/topic/en/annex_4_en.pdf.
  7. J. L. M. Christopher, “Why is Japanese life expectancy so high?” The Lancet, vol. 378, pp. 1124–1125, 2011.
  8. IARC.GLOBOCAN, http://globocan.iarc.fr/, 2008.
  9. Foundation for Promotion of Cancer Research, “Trends in crude mortality rate for leading causes of death (1947–2009),” http://www.fpcr.or.jp/pdf/statistics/fig10.pdf, 2012.
  10. T. Takeda, T. Yamaguchi, and N. Yaegashi, “Perceptions and attitudes of Japanese gynecologic cancer patients to Kampo (Japanese herbal) medicines,” International Journal of Clinical Oncology, vol. 17, pp. 143–149, 2012.
  11. K. Mori, T. Kondo, Y. Kamiyama, Y. Kano, and K. Tominaga, “Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer,” Cancer Chemotherapy and Pharmacology, vol. 51, no. 5, pp. 403–406, 2003. View at Scopus
  12. C. Sadakane, S. Muto, K. Nakagawa et al., “10-Gingerol, a component of rikkunshito, improves cisplatin-induced anorexia by inhibiting acylated ghrelin degradation,” Biochemical and Biophysical Research Communications, vol. 412, pp. 506–511, 2011.
  13. S. Ushio, N. Egashira, H. Sada et al., “Goshajinkigan reduces oxaliplatin-induced peripheral neuropathy without affecting anti-tumour efficacy in rodents,” European Journal of Cancer, vol. 48, pp. 1407–1413, 2012.
  14. M. Nishioka, M. Shimada, N. Kurita et al., “The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen,” International Journal of Clinical Oncology, vol. 16, pp. 322–327, 2011.
  15. I. Hyodo, N. Amano, K. Eguchi et al., “Nationwide survey on complementary and alternative medicine in cancer patients in Japan,” Journal of Clinical Oncology, vol. 23, no. 12, pp. 2645–2654, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Takegawa, H. Ikushima, K. Ozaki et al., “Can Kampo therapy prolong the life of cancer patients?” Journal of Medical Investigation, vol. 55, no. 1-2, pp. 99–105, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Dai, M. Kato, K. Takeda et al., “T-cell-immunity-based inhibitory effects of orally administered herbal medicine Juzen-taiho-to on the growth of primarily developed melanocytic tumors in RET-transgenic mice,” Journal of Investigative Dermatology, vol. 117, no. 3, pp. 694–701, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Tsuchiya, H. Kono, M. Matsuda, H. Fujii, and I. Rusyn, “Protective effect of Juzen-taiho-to on hepatocarcinogenesis is mediated through the inhibition of Kupffer cell-induced oxidative stress,” International Journal of Cancer, vol. 123, no. 11, pp. 2503–2511, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Watanabe, K. Matsuura, P. Gao et al., “Traditional Japanese Kampo medicine: clinical research between modernity and traditional medicine—the state of research and methodological suggestions for the future,” Evidence-based Complementary and Alternative Medicine, vol. 2011, Article ID 513842, 19 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Ikarashi, K. Ito, and T. Kimura, “Survey of the use of Kampo medicine at the Kampo Clinic: Patients' perceptions and compliance regarding Kampo medications,” Kampo Medicine, vol. 60, pp. 435–442, 2009.
  21. Treatment Manual about serious adverse events by classified disease, “Drug-induced liver injury,” http://www.info.pmda.go.jp/juutoku/file/jfm0804002.pdf, 2012.
  22. Ministry of Health, Labour and Welfare, http://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1b01.pdf.
  23. R. J. Zitnik and R. A. Matthay, “Drug-induced lung disease,” in Interstitial Lung Disease, M. I. Schwarz and T. E. King, Eds., pp. 423–449, BC Decker, Hamilton, Canada, 1998.
  24. AstraZeneca, “The results and discussions of the prospective study (Special Surveillance) for Iressa tablets 250,” http://www.mhlw.go.jp/shingi/2005/01/s0120-4.html, 2004.
  25. B. A. de Valois, T. E. Young, and E. Melsome, “Assessing the feasibility of using acupuncture and moxibustion to improve quality of life for cancer survivors with upper body lymphoedema,” European Journal of Oncology Nursing, vol. 16, pp. 301–309, 2012.